Invitrogen Shows That Not All Life Science is Created Equal
Executive Summary
Invitrogen's performance in 2003 indicates some of the variables involved in determining who can weather the pinch in life sciences spending. The company's experiences indicate that some sectors of life sciences--and thus pharma and biotech R&D--are doing well even if others are not. Invitrogen's cell culture business in particular is growing 30% a year due to changes in the nature of the market, and its new fluorescent probe business, acquired earlier this year, is also doing well.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.